Skip to content

Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance

Application of FIT-DNA Detection in Following Colorectal Cancer Resection-Implications for Surveillance

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05528783
Enrollment
200
Registered
2022-09-06
Start date
2022-04-25
Completion date
2027-01-31
Last updated
2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Colorectal cancer, FIT-DNA, Detection

Brief summary

Colorectal cancer (CRC) is a common cancer that threatens human health, with the incidence ranking the third in the world. 70% of patients are in the middle and late stages whendiagnosed, and even after radical surgery, 30% - 50% of patients with CRC have recurrence or metastasis after radical surgery. Therefore, after radical surgery and adjuvant chemotherapy, regular monitoring of CRC patients should be paid attention to in order to detect the recurrence and metastasis lesions that can be resected and the early non-invasive metachronous multiple primary tumors. The sensitivity of FIT-DNA to CRC was 95.5%, the sensitivity to advanced adenoma (AA) was 63.5%, and the specificity was 87.5%, showing a good ability to screen colorectal cancer and precancerous lesions. At present, there is no report on the application of FIT-DNA combined detection technology in the high-risk recurrence period and mid - and long-term monitoring after CRC surgery in China. In this study, Fit-DNA combined detection technology was applied to the follow-up monitoring of patients after CRC surgery, so as to optimize the current typical postoperative follow-up strategy, find early recurrence and multiple primary colorectal tumors after CRC surgery, seek the best postoperative follow-up model, improve the compliance of patients to follow-up, and ultimately benefit survival. Detailed Description:Outline:This study was a single-center, observational study. Fit-DNA detection technology was used as a target method, and colonoscopy was used as the gold standard control to follow up and monitor patients with colorectal tumors after surgery, and to explore whether it is an effective non-invasive auxiliary method for monitoring CRC recurrence and metastasis and multiple primary colorectal tumors.

Interventions

None listed

Sponsors

New Horizon Health
CollaboratorUNKNOWN
Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 1). The pathological diagnosis was colorectal adenocarcinoma; 2). Age: 18 to 80 years old,allgenders; 3). Radical surgery for CRC is required; 4). No preoperative antitumor therapy (including chemotherapy, radiation therapy, targeted therapy, and immunotherapy); 5). Preoperative examination revealed no distant metastasis; 6). There were no severe hemorrhoids or other known conditions that can cause gastrointestinal bleeding before surgery; 7). The clinical treatment data were complete;

Exclusion criteria

* 1). With a history of digestive tract tumors other than CRC; 2). Previous colorectal surgery; 3). Patients requiring a fistula; 4). With complete intestinal obstruction or perforation; 5). Women who are pregnant or breastfeeding; 6). Patients with metastases found in other sites during surgery that cannot be removed radically; 7). Patients unwilling or unable to sign an informed consent form; 8). A strict vegetarian; 9). Patients who are unwilling to follow up according to the protocol or have poor follow-up compliance; 10). Any conditions that the study physician deemed inappropriate for inclusion。 Exit or terminate criteria: 1. . Follow-up information for the patients was not available 2. . Distant metastasis was diagnosed after surgery 3. . Subjects died before the end of follow-up.

Design outcomes

Primary

MeasureTime frameDescription
The diagnostic sensitivity and specificity of FIT-DNA detection for local recurrence and advanced colorectal neoplasm of CRC.up to 5 yearsThe diagnostic sensitivity and specificity of FIT-DNA detection for local recurrence and advanced colorectal neoplasm of CRC.

Secondary

MeasureTime frameDescription
1.The AUC of FIT-DNA in recurrent CRC and advanced colorectal stage.up to 5 years1.The AUC of FIT-DNA in recurrent CRC and advanced colorectal stage.
2.NPV、PPVof FIT-DNA in recurrent CRC and advanced colorectal stage.up to 5 years2.NPV、PPVof FIT-DNA in recurrent CRC and advanced colorectal stage.
3.The time interval between CRC recurrence and advanced colorectal neogenesis after the first positive appearance was detected by FIT-DNA detection.up to 5 years3.The time interval between CRC recurrence and advanced colorectal neogenesis after the first positive appearance was detected by FIT-DNA detection.

Countries

China

Contacts

Primary ContactJunzhong Lin
linjzh@sysucc.org.cn+86-13802446666
Backup ContactZhizhong Pan
panzhzh@sysucc.org.cn+86-13719388166

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026